Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
38.58 USD | +0.21% | +3.29% | +90.52% |
05-09 | Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $61 From $59, Maintains Outperform Rating | MT |
05-08 | Transcript : Tarsus Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+90.52% | 1.45B | |
+32.36% | 709B | |
+30.77% | 595B | |
-1.60% | 367B | |
+20.07% | 334B | |
+6.04% | 289B | |
+14.77% | 239B | |
+9.13% | 211B | |
-3.97% | 203B | |
+9.27% | 171B |
- Stock Market
- Equities
- TARS Stock
- News Tarsus Pharmaceuticals, Inc.
- Transcript : Tarsus Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 03